November 29, 2024 - December 3, 2024

Suraksha Diagnostic IPO Review & Recommendations

Suraksha Diagnostic IPO Review Summary from brokers and analysts

Review By	Apply	May Apply	Neutral	Avoid	Not Rated

Suraksha Clinic and Diagnostic IPO Peer Comparison

Suraksha Diagnostic Limited peer comparison with similar listed entities. (As on March 28, 2024)

Company Name	EPS (Basic)	EPS (Diluted)	NAV (per share) (Rs)	P/E (x)	RoNW (%)	P/BV Ratio	Financial statements
Suraksha Diagnostic Limited	4.43	4.43	33.66		14.09		Consolidated
Dr Lalchandani Labs Ltd	43.05	42.98	221.47	77.08	20.35	0.07
Metropolis Healthcare Ltd	24.95	24.87	213.98	89.61	12.26	8.05
Thyrocare Technologies Ltd	13.42	13.40	99.48	65.52	13.34	5.93
Vijaya Diagnostic Centre Limited	11.62	11.59	64.21	86.40	19.77	9.91

Notes:

Closing Price per share is closing price in NSE as on July 12, 2024.
P/E is calculated as closing price / diluted EPS.
For Suraksha Diagnostic Limited, all the numbers have been taken from Restated Consolidated Financial Statements. For others, all the numbers have been sourced from the CRISIL Report.

Suraksha Diagnostic IPO Review by Members

Suraksha Diagnostic IPO Reviews, analysis and views by popular members. Read Suraksha Diagnostic Limited IPO reviews by retail investors to find recommended ipo to buy.

Post Recommendation Manage Your IPO Reviews

Suraksha Diagnostic IPO Review Summary by Members

Review By	Apply	May Apply	Neutral	Avoid
Count	0	0	1	1
%	0.00	0.00	50.00	50.00

Member	Review
Atharva G	Neutral Ipo is good but the valuation is high. Company is in profit........but the EPS is of 4.5 which is very less than peer group and the PE Of 99 which is higher than peer group. . . If valuation was good then we might have think about it. Still waiting for the last date........will see what action comes in it. 1\| November 26, 2024 12:45:22 PM
chIPOrgarh (300+ Posts)	Avoid Avoid at IPO price. Buy post listing at discounted price. EPS, NAV lowest amongst peers. 1\| November 26, 2024 10:28:47 AM

Member

Review

Atharva G

Neutral

Ipo is good but the valuation is high.
Company is in profit........but the EPS is of 4.5 which is very less than peer group and the PE Of 99 which is higher than peer group.
.
.
If valuation was good then we might have think about it.
Still waiting for the last date........will see what action comes in it.

November 26, 2024 12:45:22 PM

chIPOrgarh (300+ Posts)

Avoid

Avoid at IPO price. Buy post listing at discounted price.
EPS, NAV lowest amongst peers.

November 26, 2024 10:28:47 AM

Post Recommendation Manage Recommendations

Note:

The recommendations or analysis of public issues posted above expresses the views of its author and does not represent the views of Chittorgarh.com or its staff.
We reserve the right to remove any objectionable post without providing a reason.

Comments

Add a public comment...